Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Recombinant herpes zoster vaccine and risk of herpes zoster and death in patients with rheumatoid arthritis

Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network.

EClinicalMedicine

Citation & Authors

EClinicalMedicine. 2025;85:103319.

Ying-Li Lin; Shiow-Ing Wang; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

background

Patients with rheumatoid arthritis (RA) have an increased risk of herpes zoster (HZ). This study evaluated the effects of the recombinant zoster vaccine (RZV) on incident HZ and all-cause mortality in patients with RA.

method

This retrospective cohort study used TriNetX US Collaborative Network data from October 1, 2017, to March 31, 2024, to compare RZV-vaccinated and unvaccinated patients with RA. Propensity score matching balanced demographics, socioeconomic status, lifestyle, healthcare utilization, comorbidities, and medications. The primary outcomes were HZ and all-cause mortality. Cox proportional hazards regression calculated matched HRs, while Kaplan–Meier curves and log-rank tests assessed survival differences.

result

After matching, each group included 21,046 patients. Vaccinated patients had significantly lower risks of HZ (HR 0.836; 95% CI 0.738–0.947) and all-cause mortality (0.606; 0.561–0.654). Lower HZ risk was more pronounced in patients aged 50–64 years (0.731; 0.610–0.876), women (0.791; 0.684–0.915), White patients (0.808; 0.696–0.937), and Black/African American patients (0.685; 0.481–0.976).

Interpretation

RZV vaccination was associated with a lower risk of HZ in patients with RA aged over 50 years. Although lower all-cause mortality was observed among vaccine recipients, the magnitude of the association may not be fully explained by HZ prevention and should be interpreted cautiously. Given the established preventive effect of RZV against HZ and its potential association with lower mortality, vaccination should be prioritized for eligible patients with RA.

funding

No research funding.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.